Search

Your search keyword '"Poullin, Pascale"' showing total 174 results

Search Constraints

Start Over You searched for: Author "Poullin, Pascale" Remove constraint Author: "Poullin, Pascale"
174 results on '"Poullin, Pascale"'

Search Results

1. Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks.

2. Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome

3. Immunoadsorption and Plasma Exchange are Comparable in Anti-Neutrophil Cytoplasmic Antibodies or Anti-Glomerular Basement Membrane Removal Kinetics

5. Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience

7. Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks

8. Mortality, cardiac and cerebral damages reduction by IL-1 inhibition in a murine model of TTP

9. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

11. Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

12. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

13. Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome

14. Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience

15. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy

16. Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity

17. Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

18. Immune‐mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure

19. Aortitis is an under-recognized manifestation of antiphospholipid syndrome: A case report and literature review

22. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? experience of the French thrombotic microangiopathies reference center

23. High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center

24. Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpura

27. Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura

29. Prognostic and Long-term Survival of Immune Thrombotic Thrombocytopenic Purpura in older patients

30. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort

32. Cladribine-related immunosuppression may have fostered graft-versus-host disease after lung transplant for pulmonary Langerhans cell histiocytosis

35. Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre

36. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

37. Ineffective Erythropoiesis Negatively Impacts the Erythroblastic Island in Sickle Cell Disease

38. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center

39. Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura

40. Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis

42. Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study.

43. Comparative evaluation of the depletion-red cell exchange program with the Spectra Optia and the isovolemic hemodilution-red cell exchange method with the COBE Spectra in sickle cell disease patients.

44. Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

45. C0082 Circulating leukocyte- and endothelial-derived microparticles support a fibrinolytic activity

46. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

47. Mycosis fungoïdes and Sézary syndrome

49. First-Line Rituximab Efficacy and Safety in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Experiencing a Non Optimal Response to Therapeutical Plasma Exchange: Results of a Prospective Multicenter Phase 2 Study From the French Reference Center for the Management of Thrombotic Microangiopathies.

50. HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians.

Catalog

Books, media, physical & digital resources